AOD-9604: Storage, Reconstitution and Stability
AOD-9604 is a synthetic fragment of human growth hormone that attracted attention as a potential fat-loss agent. It is sold online as a "research peptide", usually as a freeze-dried powder, with instructions about reconstitution and storage. Our editorial team looks at what AOD-9604 actually is, where it stands legally, and why most of the handling advice circulating online should be treated with caution.
What AOD-9604 is
AOD-9604 is a modified peptide corresponding to the C-terminal region (amino acids 177–191) of human growth hormone, with an added tyrosine. This fragment was studied because the region was thought to carry some of growth hormone's fat-metabolizing activity without its effects on blood sugar or tissue growth.
In laboratory and early clinical work, the compound was investigated by an Australian biotechnology company as a potential anti-obesity drug. The scientific rationale was that it might stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without acting on the growth hormone receptor in the classical way.
Despite promising animal data, human trials were disappointing. A phase 2 clinical trial in obese participants did not show weight loss superior to placebo, which effectively ended its development as an approved obesity medication.
Because it is a peptide and not a small molecule, AOD-9604 is not orally stable in its intended form and is marketed for injection. This, together with its unproven benefits, places it squarely in the category of experimental substances rather than established therapies.
Regulatory and legal status
AOD-9604 is not approved by the US Food and Drug Administration (FDA) as a drug for any indication. It is not a dietary ingredient either; the FDA has stated that peptides like this do not qualify as dietary supplements, and products marketing them as such are considered misbranded or unapproved drugs.
Vials sold online are typically labeled "for research use only, not for human consumption". That label is a legal device used by sellers; it does not mean the product has been tested for purity or sterility, and it does not make human use legal or safe.
For competitive athletes, the situation is clear-cut. The World Anti-Doping Agency (WADA) prohibits growth hormone fragments and related peptides under section S2 of its list. Using AOD-9604 can lead to a doping sanction.
Internationally, status varies. In Australia, where it originated, AOD-9604 has been placed in a prescription-only category. In the US and UK, selling it for human use without approval is unlawful. Buyers of "research" vials have no consumer protections if something goes wrong.
The chemistry of peptide stability
Peptides are chains of amino acids held together by peptide bonds. They are inherently more fragile than small-molecule drugs because they can degrade through several chemical and physical routes: hydrolysis of bonds, oxidation of certain residues, deamidation, and aggregation of unfolded chains.
Freeze-drying (lyophilization) removes water and slows these reactions, which is why research peptides are shipped as dry powder. Once a peptide is dissolved, the clock starts: degradation generally accelerates in solution, at higher temperatures, and at extremes of pH.
| Factor | Effect on a dissolved peptide |
|---|---|
| Temperature | Higher temperatures speed up most degradation reactions |
| Light | Can promote oxidation of sensitive residues |
| Repeated freeze–thaw | Mechanical stress can cause aggregation |
| pH extremes | Accelerate hydrolysis and deamidation |
| Microbial contamination | Spoils non-preserved solutions and poses infection risk |
These principles are general pharmaceutical science. They explain why manufacturers of approved peptide drugs specify exact storage temperatures and expiry dates validated by stability testing, information that grey-market products simply do not have.
A figure often cited online is that reconstituted peptides "last a few weeks refrigerated". In reality, shelf life depends on the specific peptide, the solvent, preservatives and sterility, none of which is standardized for unregulated products.
Reconstitution and storage principles
For any legitimate injectable medicine, reconstitution is performed according to the manufacturer's validated instructions, with sterile technique, in a clinical or pharmacy setting. The solvent, volume and storage conditions are part of the approved product information.
Because AOD-9604 has no such approved product information for general use, any online "reconstitution guide" is based on unverified assumptions. There is no reliable way for a consumer to confirm the identity, concentration or sterility of what is in the vial.
The infection risk from self-injecting non-sterile solutions is real and includes abscesses and bloodborne infections. This is a core reason medical authorities discourage use of grey-market injectables regardless of the molecule involved.
In short, the practical "how to store it" question cannot be answered responsibly for an unapproved product, because the inputs needed to answer it, validated stability data and quality control, do not exist.
Why the evidence and products are uncertain
The clinical case for AOD-9604 as a fat-loss agent is weak. The pivotal human obesity trial did not demonstrate meaningful weight loss, and no large, high-quality trials have since reversed that conclusion.
Independent analyses of peptides sold online have repeatedly found discrepancies between labeled and actual contents, including wrong quantities and impurities. A buyer cannot assume the vial contains what the label says.
Marketing often borrows the language of the original research to imply proven benefits. Reading closely, most claims rest on animal studies or laboratory findings, not on positive human outcomes.
For anyone whose goal is fat loss, established approaches, nutrition, training, sleep and, where appropriate, physician-supervised medications, have far stronger evidence and known safety profiles than an unapproved peptide.
Editorial conclusions
AOD-9604 is a growth-hormone fragment that failed to show meaningful fat-loss benefit in human trials and is not approved for use in the US or UK. It is prohibited in sport.
The general chemistry of peptide stability explains why approved peptide drugs carry precise storage rules, but those rules depend on data that grey-market products lack. That makes responsible "storage advice" for AOD-9604 impossible to give.
The safest reading of the evidence is that AOD-9604 offers unproven benefits alongside real legal and health risks.
Related editorial reading: how peptide drugs are regulated in the US, why "research only" labels are misleading, and evidence-based approaches to fat loss.
References
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442–1449.
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278.
- World Anti-Doping Agency. The Prohibited List. Montreal: WADA; 2024.
- US Food and Drug Administration. Statement on dietary supplements and peptide products. Silver Spring, MD: FDA; 2019.
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575.
- Vigneri R, Goldfine ID. The use of growth hormone and its fragments in metabolic disease: a critical review. Endocr Rev. 2009;30(2):152–177.
